BioStem Technologies Past Earnings Performance
Past criteria checks 0/6
BioStem Technologies's earnings have been declining at an average annual rate of -11.1%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 142.7% per year.
Key information
-11.1%
Earnings growth rate
7.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 142.7% |
| Return on equity | n/a |
| Net Margin | -47.1% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How BioStem Technologies makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 17 | -8 | 22 | 0 |
| 30 Sep 23 | 6 | -9 | 14 | 0 |
| 30 Jun 23 | 4 | -11 | 13 | 0 |
| 31 Mar 23 | 5 | -8 | 11 | 0 |
| 31 Dec 22 | 7 | -7 | 10 | 0 |
| 30 Sep 22 | 7 | -4 | 7 | 0 |
| 30 Jun 22 | 7 | -4 | 7 | 0 |
| 31 Mar 22 | 6 | -4 | 7 | 0 |
| 31 Dec 21 | 4 | -1 | 4 | 0 |
| 30 Jun 18 | 0 | -4 | 4 | 0 |
| 31 Mar 18 | 0 | -5 | 5 | 0 |
| 31 Dec 17 | 0 | -5 | 5 | 0 |
| 30 Sep 17 | 0 | -3 | 3 | 0 |
| 30 Jun 17 | 0 | -4 | 4 | 0 |
| 31 Mar 17 | 1 | -3 | 4 | 0 |
| 31 Dec 16 | 1 | -4 | 4 | 0 |
| 30 Sep 16 | 1 | -6 | 6 | 0 |
| 30 Jun 16 | 1 | -4 | 4 | 0 |
| 31 Mar 16 | 0 | -3 | 3 | 0 |
| 31 Dec 15 | 0 | -2 | 2 | 0 |
| 30 Sep 15 | 0 | -1 | 1 | 0 |
Quality Earnings: BSEM is currently unprofitable.
Growing Profit Margin: BSEM is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if BSEM's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare BSEM's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BSEM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: BSEM's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.